Body fat distribution: a crucial target for intervention in nonalcoholic fatty liver disease and fibrosis.
作者信息
Wijarnpreecha Karn, Ahmed Aijaz, Kim Donghee
机构信息
Division of Gastroenterology and Hepatology, Department of Medicine, University of Arizona College of Medicine, Phoenix, AZ, USA.
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Banner University Medical Center, Phoenix, AZ, USA.
出版信息
Hepatobiliary Surg Nutr. 2022 Oct;11(5):738-742. doi: 10.21037/hbsn-22-366.
Abstract
摘要
相似文献
1
Body fat distribution: a crucial target for intervention in nonalcoholic fatty liver disease and fibrosis.体脂分布：非酒精性脂肪性肝病和肝纤维化干预的关键靶点。
Hepatobiliary Surg Nutr. 2022 Oct;11(5):738-742. doi: 10.21037/hbsn-22-366.
2
Efficacy of Sitagliptin on Nonalcoholic Fatty Liver Disease in High-fat-diet-fed Diabetic Mice.西他列汀对高脂饮食喂养糖尿病小鼠非酒精性脂肪性肝病的疗效。
Curr Med Sci. 2022 Jun;42(3):513-519. doi: 10.1007/s11596-022-2573-9. Epub 2022 Apr 22.
3
Predictors of nonalcoholic steatohepatitis and significant fibrosis in non-obese nonalcoholic fatty liver disease.非肥胖非酒精性脂肪性肝病中非酒精性肝炎和显著纤维化的预测因素。
Liver Int. 2019 Feb;39(2):332-341. doi: 10.1111/liv.13983. Epub 2018 Oct 27.
4
A comparison of the fibrotic potential of nonalcoholic fatty liver disease and chronic hepatitis C.非酒精性脂肪性肝病与慢性丙型肝炎纤维化潜能的比较。
Hum Pathol. 2010 Aug;41(8):1178-85. doi: 10.1016/j.humpath.2009.10.025. Epub 2010 Apr 22.
5
Myosteatosis in nonalcoholic fatty liver disease: An exploratory study.非酒精性脂肪性肝病中的肌内脂肪变性：一项探索性研究。
Clin Res Hepatol Gastroenterol. 2021 May;45(3):101500. doi: 10.1016/j.clinre.2020.06.021. Epub 2020 Aug 20.
6
[The expression and significance of osteopontin in the development of nonalcoholic fatty liver fibrosis in rats].[骨桥蛋白在大鼠非酒精性脂肪性肝纤维化发生发展中的表达及意义]
Zhonghua Gan Zang Bing Za Zhi. 2008 Nov;16(11):831-4.
7
IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.2 型糖尿病对非酒精性脂肪性肝病患者非酒精性脂肪性肝炎和肝纤维化进展的影响。
Endocr Pract. 2020 Apr;26(4):444-453. doi: 10.4158/EP-2019-0342. Epub 2020 Jan 22.
8
PNPLA3 I148M variant in nonalcoholic fatty liver disease: demographic and ethnic characteristics and the role of the variant in nonalcoholic fatty liver fibrosis.非酒精性脂肪性肝病中的PNPLA3 I148M变异：人口统计学和种族特征以及该变异在非酒精性脂肪性肝纤维化中的作用
World J Gastroenterol. 2015 Jan 21;21(3):794-802. doi: 10.3748/wjg.v21.i3.794.
9
Relationship between nonalcoholic fatty liver disease prevalence and visceral fat in obese adolescents.肥胖青少年非酒精性脂肪性肝病患病率与内脏脂肪的关系。
Dig Liver Dis. 2008 Feb;40(2):132-9. doi: 10.1016/j.dld.2007.09.009. Epub 2007 Dec 21.
10
Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD.血清胆汁酸模式与双胞胎中非酒精性脂肪性肝病（NAFLD）的存在相关，并且在经活检证实的非酒精性脂肪性肝病患者中，随着纤维化阶段的增加，呈现出剂量依赖性变化。
Aliment Pharmacol Ther. 2019 Jan;49(2):183-193. doi: 10.1111/apt.15035. Epub 2018 Dec 2.
引用本文的文献
1
Long-term outcomes and risk modifiers of metabolic dysfunction-associated steatotic liver disease between lean and non-lean populations.瘦人群与非瘦人群中代谢功能障碍相关脂肪性肝病的长期结局及风险修饰因素
Clin Mol Hepatol. 2025 Jan;31(1):74-89. doi: 10.3350/cmh.2024.0631. Epub 2024 Oct 23.
2
Association between Body Fat Distribution and Nonalcoholic Fatty Liver Disease/Fibrosis Based on Race/Ethnicity.基于种族/民族的体脂分布与非酒精性脂肪性肝病/肝纤维化之间的关联。
J Obes Metab Syndr. 2024 Dec 30;33(4):326-336. doi: 10.7570/jomes24005. Epub 2024 Oct 21.
3
CRISPR-edited hepatic organoids as drug screening platform for non-alcoholic fatty liver disease.经CRISPR编辑的肝类器官作为非酒精性脂肪性肝病的药物筛选平台
Hepatobiliary Surg Nutr. 2023 Aug 1;12(4):593-594. doi: 10.21037/hbsn-23-247. Epub 2023 Jul 6.
本文引用的文献
1
Body fat distribution and insulin resistance among Korean middle-aged women: a Korean National Health and Nutrition Examination Survey.韩国中年女性的体脂分布与胰岛素抵抗：一项韩国国家健康与营养检查调查
Obstet Gynecol Sci. 2022 Sep;65(5):468-476. doi: 10.5468/ogs.22001. Epub 2022 Jul 29.
2
Adipose tissue dysfunction and visceral fat are associated with hepatic insulin resistance and severity of NASH even in lean individuals.即使在体型偏瘦的个体中，脂肪组织功能障碍和内脏脂肪也与肝脏胰岛素抵抗及非酒精性脂肪性肝炎的严重程度相关。
Liver Int. 2022 Nov;42(11):2418-2427. doi: 10.1111/liv.15377. Epub 2022 Aug 18.
3
Silhouette images enable estimation of body fat distribution and associated cardiometabolic risk.侧面影像有助于评估身体脂肪分布及相关的心脏代谢风险。
NPJ Digit Med. 2022 Jul 27;5(1):105. doi: 10.1038/s41746-022-00654-1.
4
Sex-related association of nonalcoholic fatty liver disease and liver fibrosis with body fat distribution in the general US population.非酒精性脂肪性肝病和肝纤维化与美国普通人群体脂分布的性别相关性。
Am J Clin Nutr. 2022 Jun 7;115(6):1528-1534. doi: 10.1093/ajcn/nqac059.
5
Women Have a Lower Risk of Nonalcoholic Fatty Liver Disease but a Higher Risk of Progression vs Men: A Systematic Review and Meta-analysis.女性患非酒精性脂肪性肝病的风险较低，但进展为该病的风险高于男性：系统评价和荟萃分析。
Clin Gastroenterol Hepatol. 2021 Jan;19(1):61-71.e15. doi: 10.1016/j.cgh.2020.04.067. Epub 2020 Apr 30.
6
Effect of longitudinal changes of body fat on the incidence and regression of nonalcoholic fatty liver disease.体脂肪含量纵向变化对非酒精性脂肪性肝病发病和逆转的影响。
Dig Liver Dis. 2018 Apr;50(4):389-395. doi: 10.1016/j.dld.2017.12.014. Epub 2017 Dec 26.
7
Visceral Obesity Predicts Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.内脏肥胖可预测非酒精性脂肪性肝病患者的显著纤维化。
Medicine (Baltimore). 2015 Dec;94(48):e2159. doi: 10.1097/MD.0000000000002159.
8
Body Fat Distribution and Risk of Incident and Regressed Nonalcoholic Fatty Liver Disease.体脂分布与非酒精性脂肪性肝病发病和消退风险。
Clin Gastroenterol Hepatol. 2016 Jan;14(1):132-8.e4. doi: 10.1016/j.cgh.2015.07.024. Epub 2015 Jul 27.
9
Visceral adipose tissue area as an independent risk factor for elevated liver enzyme in nonalcoholic fatty liver disease.内脏脂肪组织面积作为非酒精性脂肪性肝病中肝酶升高的独立危险因素。
Medicine (Baltimore). 2015 Mar;94(9):e573. doi: 10.1097/MD.0000000000000573.
10
Sagittal abdominal diameter is a strong anthropometric measure of visceral adipose tissue in the Asian general population.矢状腹部直径是亚洲普通人群内脏脂肪组织的强有力的人体测量学指标。
Diabetes Care. 2010 Dec;33(12):2665-70. doi: 10.2337/dc10-0606. Epub 2010 Sep 15.
Zotero 插件